Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Ali BazarbachiAriane BoumendilHervé FinelMohamad MohtyLuca CastagnaDidier BlaiseKarl S PeggsBoris AfanasyevJ L Diez-MartinPaolo CorradiniDavid MichonneauStephen RobinsonGonzalo Gutiérrez GarcíaFrancesca BonifaziIbrahim Yakoub-AghaZafer GülbasAdrian BloorJeremy DelageAlbert EsquirolRam MalladiChristof ScheidJean El-CheikhHervé GhesquièresSilvia MontotoPeter DregerAnna Sureda

Published in: Cancer (2018)

BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.

Keyphrases

hodgkin lymphoma
allogeneic hematopoietic stem cell transplantation
lps induced
lipopolysaccharide induced
acute myeloid leukemia
acute lymphoblastic leukemia
inflammatory response
diffuse large b cell lymphoma
free survival